Stuart Schreiber

Quick Facts

Full Name	Stuart Schreiber
Occupation	Biochemist
Date Of Birth	Feb 6, 1956(1956-02-06)
Age	68
Country	United States
Birth City	Virginia
Horoscope	Aquarius

Stuart Schreiber Biography

Stuart Schreiber is one of the most popular and richest Biochemist who was born on February 6, 1956 in Virginia, United States. Stuart L. Schreiber (born 6 February 1956) is an academic Scientist in Harvard University and co-Founder of the Broad Institute. He is active in the field of chemical biology, particularly the application of small molecules as probes for the biology of medicine and. Small molecules are those of life with the highest affinity for the flow of information in a dynamic manner. They interact with macromolecules (DNA and RNA, proteins) that form the foundation for inheritance of information flow.

The year 1994 was the time that Schreiber along with co-workers conducted research on (independently in collaboration with David Sabitini) the master regulator of nutrient sensing, called mTOR. They discovered that the tiny molecules rapamycin both bind to FKBP12 and MTOR (originally known as FKBP12-rapamycin binding, also known as FRAP). Through diversity-oriented synthesis and small-molecule analysis, Schreiber revealed the nutrient- response signaling system that is a part of TOR proteins in yeast as well as the mammalian mTOR. Small molecules like the uretupamine and rapamycin have been shown to be extremely effective in revealing the capability of proteins like MTOR Tor1p, Tor2p, and Ure2p to accept multiple inputs and be able to process them in a manner that produces multiple outputs (in similar fashion to multichannel processors). Many pharmaceutical companies are looking at the nutrient-signaling system to treat a variety of types of cancer which includes solid tumors.

In 1996, Schreiber and co-workers used the small molecules trapoxin and depudecin to investigate the histone deacetylases (HDACs). Prior to Schreiber’s work in this area, the HDAC proteins had not been isolated. Coincident with the HDAC work, David Allis and colleagues reported work on the histone acetyltransferases (HATs). These two contributions catalyzed much research in this area, eventually leading to the characterization of numerous histone-modifying enzymes, their resulting histone “marks”, and numerous proteins that bind to these marks. By taking a global approach to understanding chromatin function, Schreiber proposed a “signaling network model” of chromatin and compared it to an alternative view, the “histone code hypothesis” presented by Strahl and Allis. These studies shined a bright light on chromatin as a key gene expression regulatory element rather than simply a structural element used for DNA compaction.

Schreiber applied small molecules to biology through the development of diversity-oriented synthesis (DOS), chemical genetics, and ChemBank. Schreiber has shown that DOS can produce small molecules distributed in defined ways in chemical space by virtue of their different skeletons and stereochemistry, and that it can provide chemical handles on products anticipating the need for follow-up chemistry using, for example, combinatorial synthesis and the so- called Build/Couple/Pair strategy of modular chemical synthesis. DOS pathways and new techniques for small-molecule screening provided many new, potentially disruptive insights into biology. Small-molecule probes of histone and tubulin deacetylases, transcription factors, cytoplasmic anchoring proteins, developmental signaling proteins (e.g., histacin, tubacin, haptamide, uretupamine, concentramide, and calmodulophilin), among many others, have been uncovered in the Schreiber lab using diversity-oriented synthesis and chemical genetics. Multidimensional screening was introduced in 2002 and has provided insights into tumorigenesis, cell polarity, and chemical space, among others.

in 1993 Schreiber along with Crabtree came up with “small-molecule dimerizers”, which allow small-molecule activation of a variety of signaling pathways and molecules (e.g. TGFb, Fas TGFb, insulin, as well as T-cell receptors) via proximity effects. Schreiber and Crabtree proved that small molecules can activate the signaling pathway of animals that have the ability to control spatial and temporal time. Dimerizer kits are distributed without charge, resulting in a number of peer-reviewed articles. Its potential in the field of gene therapy was shown by the capacity of a tiny molecule to trigger a small-molecule controlled EPO receptor, and also to trigger an erythropoiesis (Ariad Pharmaceuticals, Inc.) and more recently, in human clinical trials in the treatment of graft-versus-host diseases.

Stuart Schreiber Net Worth

Stuart Schreiber is one of the richest Biochemist from United States. According to our analysis, Wikipedia, Forbes & Business Insider, Stuart Schreiber 's net worth $5 Million. (Last Update: December 11, 2023)

Schreiber received the bachelor of Science degree in chemistry at the University of Virginia in 1977 following which he enrolled at Harvard University as a graduate student in Chemistry. He joined the research team that was led by Robert B. Woodward and after the death of Woodward pursued his research under the guidance under the direction of Yoshito Kishi. In 1980 when he was appointed to the faculty at Yale University as an assistant professor of Chemistry In 1988, He moved back to Harvard University as the Morris Loeb Professor.

Following his work on the FK506-binding protein FKBP12 in 1988, Schreiber reported that the small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-ciclosporin-calcineurin. This work, together with work by Gerald Crabtree at Stanford University concerning the NFAT proteins, led to the elucidation of the calcium-calcineurin-NFAT signaling pathway. The Ras-RafMAPK pathway wasn’t discovered until the following year.

In 1995, Schreiber and co-workers found that the small molecule lactacystin binds and inhibits specific catalytic subunits of the proteasome, a protein complex responsible for the bulk of proteolysis in the cell, as well as proteolytic activation of certain protein substrates. As a non-peptidic proteasome inhibitor lactacysin has proven useful in the study of proteasome function. Lactacystin modifies the amino-terminal threonine of specific proteasome subunits. This work helped to establish the proteasome as a mechanistically novel class of protease: an amino-terminal threonine protease. The work led to the use of bortezomib to treat multiple myeloma.

Height, Weight & Body Measurements

Stuart Schreiber height Not available right now. Stuart weight Not Known & body measurements will update soon.

Who is Stuart Schreiber Dating?

According to our records, Stuart Schreiber is possibily single & has not been previously engaged. As of December 1, 2023, Stuart Schreiber’s is not dating anyone.

Relationships Record : We have no records of past relationships for Stuart Schreiber. You may help us to build the dating records for Stuart Schreiber!

Facts & Trivia

Stuart Ranked on the list of most popular Biochemist. Also ranked in the elit list of famous people born in United States. Stuart Schreiber celebrates birthday on February 6 of every year.

Top Facts about Stuart Schreiber

1. Stuart Schreiber is an American chemist and entrepreneur.
2. He co-founded Vertex Pharmaceuticals, a biotech company.
3. Schreiber has won numerous awards for his research in chemistry.
4. He is a professor at Harvard University and Broad Institute.
5. Schreiber’s work focuses on chemical biology and drug discovery.
6. He has published over 500 scientific papers and holds multiple patents.
7. Schreiber was elected to the National Academy of Sciences in 1996.
8. His research has led to the development of several FDA-approved drugs.
9. Schreiber is known for his innovative approaches to drug discovery.
10. He advocates for open science and collaboration in research efforts.